| Year |
Citation |
Score |
| 2024 |
Geva R, Vieito M, Ramon J, Perets R, Pedregal M, Corral E, Doger B, Calvo E, Bardina J, Garralda E, Brown RJ, Greger JG, Wu S, Steinbach D, Yao TS, ... Cao Y, et al. Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors. Cancer Immunology, Immunotherapy : Cii. 73: 205. PMID 39105878 DOI: 10.1007/s00262-024-03790-7 |
0.326 |
|
| 2024 |
Zhao L, Li S, Wei X, Qi X, Guo Q, Shi L, Zhang JS, Li J, Liu ZL, Guo Z, Zhang H, Feng J, Shi Y, Zhang S, Cao YJ. A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances. Protein & Cell. PMID 38823002 DOI: 10.1093/procel/pwae034 |
0.591 |
|
| 2024 |
Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, Lu Y, Xue J. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduction and Targeted Therapy. 9: 126. PMID 38773064 DOI: 10.1038/s41392-024-01826-z |
0.348 |
|
| 2024 |
Mandula JK, Sierra-Mondragon RA, Jimenez RV, Chang D, Mohamed E, Chang S, Vazquez-Martinez JA, Cao Y, Anadon CM, Lee SB, Das S, Rocha-Munguba L, Pham VM, Li R, Tarhini AA, et al. Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. Immunity. PMID 38636522 DOI: 10.1016/j.immuni.2024.03.020 |
0.31 |
|
| 2024 |
Hu R, Cao Y, Wang Y, Zhao T, Yang K, Fan M, Guan M, Hou Y, Ying J, Ma X, Deng N, Sun X, Zhang Y, Zhang X. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. Breast Cancer Research : Bcr. 26: 48. PMID 38504374 DOI: 10.1186/s13058-024-01802-z |
0.315 |
|
| 2023 |
He M, Zhang D, Cao Y, Chi C, Zeng Z, Yang X, Yang G, Sharma K, Hu K, Enikeev M. Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects. Heliyon. 9: e19147. PMID 37664750 DOI: 10.1016/j.heliyon.2023.e19147 |
0.344 |
|
| 2023 |
Cao Y, Efetov SK, He M, Fu Y, Beeraka NM, Zhang J, Zhang X, Bannimath N, Chen K. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. Archivum Immunologiae Et Therapiae Experimentalis. 71: 19. PMID 37566162 DOI: 10.1007/s00005-023-00684-x |
0.393 |
|
| 2023 |
Wen J, Huang Q, Yao J, Wei W, Li Z, Zhang H, Chang S, Pei H, Cao Y, Li H. Focusing on scRNA-seq-Derived T Cell-Associated Genes to Identify Prognostic Signature and Immune Microenvironment Status in Low-Grade Glioma. Mediators of Inflammation. 2023: 3648946. PMID 37292257 DOI: 10.1155/2023/3648946 |
0.315 |
|
| 2023 |
Jiang H, Suo H, Gao L, Liu Y, Chen B, Lu S, Jin F, Cao Y. Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer. International Immunopharmacology. 118: 110038. PMID 36996738 DOI: 10.1016/j.intimp.2023.110038 |
0.338 |
|
| 2022 |
Qiu Y, Qi Z, Wang Z, Cao Y, Lu L, Zhang H, Mathes D, Pomfret EA, Lu SL, Wang Z. EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models. Oncology Reports. 49. PMID 36579667 DOI: 10.3892/or.2022.8474 |
0.322 |
|
| 2022 |
Liu D, Qi X, Wei X, Zhao L, Wang X, Li S, Wang Z, Shi L, Xu J, Hong M, Liu Z, Zhao L, Wang X, Zhang B, Zhang Y, ... ... Cao YJ, et al. A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy. Theranostics. 12: 7788-7803. PMID 36451856 DOI: 10.7150/thno.75037 |
0.779 |
|
| 2022 |
Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, Wen F, Zhang JS, Wang F, Liu ZL, Cao YJ. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. PMID 35981465 DOI: 10.1182/blood.2022016243 |
0.625 |
|
| 2021 |
Xia Y, Li X, Yang L, Luo X, Shen W, Cao Y, Peplowski L, Chen X. Development of thermostable sucrose phosphorylase by semi-rational design for efficient biosynthesis of alpha-D-glucosylglycerol. Applied Microbiology and Biotechnology. PMID 34542685 DOI: 10.1007/s00253-021-11551-0 |
0.502 |
|
| 2021 |
Cao YJ, Yu C, Wu KL, Wang X, Liu D, Tian Z, Zhao L, Qi X, Loredo A, Chung A, Xiao H. Synthesis of precision antibody conjugates using proximity-induced chemistry. Theranostics. 11: 9107-9117. PMID 34522229 DOI: 10.7150/thno.62444 |
0.68 |
|
| 2021 |
Bloom JA, Sekigami Y, Young R, Macera L, Russell CA, Cao Y, Buchsbaum RJ, Naber SP, Chatterjee A. Discordance in Oncotype DX Breast Recurrence Score Results for Bilateral Breast Cancer. Annals of Surgical Oncology. PMID 34241750 DOI: 10.1245/s10434-021-10387-2 |
0.452 |
|
| 2021 |
Cao YJ, Wang X, Wang Z, Zhao L, Li S, Zhang Z, Wei X, Yun H, Choi SH, Liu Z, Zhao L, Kazane SA. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. Acs Synthetic Biology. PMID 33856201 DOI: 10.1021/acssynbio.1c00007 |
0.832 |
|
| 2021 |
Li C, Cao Y, Zhang L, Li J, Wang J, Zhou Y, Wei H, Guo M, Liu L, Liu C, Zhang S, Liu G. CRISPR-CasRx Targeting LncRNA LINC00341 Inhibits Tumor Cell Growth and . Frontiers in Molecular Biosciences. 8: 638995. PMID 33855047 DOI: 10.3389/fmolb.2021.638995 |
0.322 |
|
| 2021 |
Sekigami Y, Char S, Mullen C, Huber K, Cao Y, Buchsbaum R, Graham R, Nardello S, Singhal D, Chatterjee A. Cost-Effectiveness Analysis: Lymph Node Transfer vs Lymphovenous Bypass for Breast Cancer-Related Lymphedema. Journal of the American College of Surgeons. PMID 33684564 DOI: 10.1016/j.jamcollsurg.2021.02.013 |
0.421 |
|
| 2020 |
Sun X, Zhang L, Cao Y, Li J, Atanasov AG, Huang L. Anti-neuraminidase Activity of Chemical Constituents of Balanophora Involucrata. Biomedical Chromatography : Bmc. e4949. PMID 32678491 DOI: 10.1002/bmc.4949 |
0.343 |
|
| 2020 |
Wang Z, Cao YJ. Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research. Frontiers in Immunology. 11: 176. PMID 32194541 DOI: 10.3389/Fimmu.2020.00176 |
0.674 |
|
| 2020 |
Ding X, Huang T, Peng C, Ahn KS, Andersen JB, Lewinska M, Cao Y, Xu G, Chen G, Kong B, Friess H, Shen S, Roberts LR, Wang L, Zou X. Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma. Journal of Cancer. 11: 2241-2251. PMID 32127951 DOI: 10.7150/jca.31989 |
0.315 |
|
| 2019 |
Zhao L, Cao YJ. Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology. 10: 2250. PMID 31681259 DOI: 10.3389/Fimmu.2019.02250 |
0.627 |
|
| 2019 |
Cheung LH, Zhao Y, Alvarez-Cienfuegos A, Mohamedali KA, Cao YJ, Hittelman WN, Rosenblum MG. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B. Journal of Experimental & Clinical Cancer Research : Cr. 38: 332. PMID 31362764 DOI: 10.1186/S13046-019-1333-6 |
0.632 |
|
| 2019 |
Zhang Y, Fang C, Wang RE, Wang Y, Guo H, Guo C, Zhao L, Li S, Li X, Schultz PG, Cao YJ, Wang F. A tumor-targeted immune checkpoint blocker. Proceedings of the National Academy of Sciences of the United States of America. PMID 31332018 DOI: 10.1073/Pnas.1905646116 |
0.798 |
|
| 2019 |
Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, et al. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications. 10: 1280. PMID 30894532 DOI: 10.1038/S41467-019-09263-1 |
0.384 |
|
| 2017 |
Du J, Cao Y, Liu Y, Wang Y, Zhang Y, Fu G, Zhang Y, Lu L, Luo X, Kim CH, Schultz PG, Wang F. Engineering Bifunctional Antibodies with Constant Region Fusion Architectures. Journal of the American Chemical Society. PMID 29186655 DOI: 10.1021/Jacs.7B09641 |
0.802 |
|
| 2017 |
Li L, Cui D, Ye L, Li Y, Zhu L, Yang L, Bai B, Nie Z, Gao J, Cao Y. Codelivery of salinomycin and docetaxel using poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles to target both gastric cancer cells and cancer stem cells. Anti-Cancer Drugs. PMID 28692437 DOI: 10.1097/Cad.0000000000000541 |
0.314 |
|
| 2016 |
Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, Mazagova M, Choi SH, Yun HY, Xiao H, Yang P, Luo X, Lim RK, Pugh HM, Wang F, et al. Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. Angewandte Chemie (International Ed. in English). 55: 7520-4. PMID 27145250 DOI: 10.1002/Anie.201601902 |
0.786 |
|
| 2016 |
Wu X, Cao Y, Zhang J, Lei M, Deng X, Zahid KR, Liu Y, Liu K, Yang J, Xiong G, Yao H, Qi C. Determination of glutathione in apoptotic SMMC-7221 cells induced by xylitol selenite using capillary electrophoresis. Biotechnology Letters. PMID 26892224 DOI: 10.1007/s10529-016-2056-9 |
0.447 |
|
| 2016 |
Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America. 113: E459-68. PMID 26759369 DOI: 10.1073/Pnas.1524155113 |
0.826 |
|
| 2016 |
Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, ... ... Cao Y, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences of the United States of America. 113: E450-8. PMID 26759368 DOI: 10.1073/Pnas.1524193113 |
0.802 |
|
| 2015 |
Liu Y, Zhai L, Yao S, Cao Y, Cao Y, Zhang X, Su J, Ge Y, Zhao R, Cheng C. Brachybacterium hainanense sp. nov., isolated from Noni (Morinda citrifolia L.) branch. International Journal of Systematic and Evolutionary Microbiology. PMID 26311250 DOI: 10.1099/ijsem.0.000559 |
0.422 |
|
| 2015 |
Bull-Hansen B, Berstad MB, Berg K, Cao Y, Skarpen E, Fremstedal AS, Rosenblum MG, Peng Q, Weyergang A. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer. Oncotarget. 6: 12436-51. PMID 26002552 DOI: 10.18632/Oncotarget.3814 |
0.573 |
|
| 2015 |
Lim RK, Yu S, Cheng B, Li S, Kim NJ, Cao Y, Chi V, Kim JY, Chatterjee AK, Schultz PG, Tremblay MS, Kazane SA. Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate. Bioconjugate Chemistry. 26: 2216-22. PMID 25945727 DOI: 10.1021/Acs.Bioconjchem.5B00203 |
0.798 |
|
| 2015 |
Cao Y, Axup JY, Ma JS, Wang RE, Choi S, Tardif V, Lim RK, Pugh HM, Lawson BR, Welzel G, Kazane SA, Sun Y, Tian F, Srinagesh S, Javahishvili T, et al. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Angewandte Chemie (International Ed. in English). 54: 7022-7. PMID 25919418 DOI: 10.1002/Anie.201500799 |
0.799 |
|
| 2015 |
Wang RE, Liu T, Wang Y, Cao Y, Du J, Luo X, Deshmukh V, Kim CH, Lawson BR, Tremblay MS, Young TS, Kazane SA, Wang F, Schultz PG. An immunosuppressive antibody-drug conjugate. Journal of the American Chemical Society. 137: 3229-32. PMID 25699419 DOI: 10.1021/Jacs.5B00620 |
0.785 |
|
| 2015 |
Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, Gonzalez J, Schultz PG, Young TS, Kim CH. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. Journal of the American Chemical Society. 137: 2832-5. PMID 25692571 DOI: 10.1021/Jacs.5B00106 |
0.826 |
|
| 2015 |
Reuben A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Haymaker C, Chen P, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget M, Gopalakrishnan V, et al. Molecular and immune heterogeneity in synchronous melanoma metastases Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P262 |
0.344 |
|
| 2015 |
Garber HR, Beird H, Cao Y, Zhang J, Sargent R, Lin P, Seth S, Song X, Sun H, Mao X, John LS, Clise-Dwyer K, Alatrash G, Futreal PA, Molldrem JJ. Abstract LB-222: Long-term subclonal evolution of CLL from immune selective pressure after allogeneic stem cell transplant and donor lymphocyte infusion Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-222 |
0.33 |
|
| 2015 |
Reuben A, Cooper ZA, Roh W, Cao Y, Austin-Breneman J, Jiang H, Amaria RN, Chen P, Tetzlaff MT, Chin L, Futreal A, Davies MA, Wargo JA. Abstract 1301: Inter- and intra-tumoral immune and genomic heterogeneity in patients with metastatic melanoma Cancer Research. 75: 1301-1301. DOI: 10.1158/1538-7445.Am2015-1301 |
0.349 |
|
| 2014 |
Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Molecular Cancer Therapeutics. 13: 2688-705. PMID 25239934 DOI: 10.1158/1535-7163.Mct-14-0346 |
0.633 |
|
| 2014 |
Furman JL, Kang M, Choi S, Cao Y, Wold ED, Sun SB, Smider VV, Schultz PG, Kim CH. A genetically encoded aza-Michael acceptor for covalent cross-linking of protein-receptor complexes. Journal of the American Chemical Society. 136: 8411-7. PMID 24846839 DOI: 10.1021/Ja502851H |
0.747 |
|
| 2014 |
Bull-Hansen B, Cao Y, Berg K, Skarpen E, Rosenblum MG, Weyergang A. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome. Journal of Controlled Release : Official Journal of the Controlled Release Society. 182: 58-66. PMID 24637464 DOI: 10.1016/J.Jconrel.2014.03.014 |
0.604 |
|
| 2014 |
Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. Plos One. 9: e90362. PMID 24587339 DOI: 10.1371/Journal.Pone.0090362 |
0.327 |
|
| 2014 |
Zhang S, Cao Y, Xie L, Qiao D, Cao Y. Effect of superoxide dismutase‑entrapped liposomes and protein transduction domain‑superoxide dismutase on human umbilical vein endothelial cells. Molecular Medicine Reports. 9: 1427-33. PMID 24567128 DOI: 10.3892/Mmr.2014.1970 |
0.31 |
|
| 2014 |
Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene. 33: 429-39. PMID 23376850 DOI: 10.1038/Onc.2012.612 |
0.624 |
|
| 2014 |
Zhou H, Mohamedali KA, Cao Y, Migliorini M, Cheung LH, Hittelman WN, Winkles JA, Rosenblum MG. Abstract 4512: Construction and characterization of novel, human serine protease granzyme B-based cancer therapeutics targeting the TNFR family member Fn14 Cancer Research. 74: 4512-4512. DOI: 10.1158/1538-7445.Am2014-4512 |
0.649 |
|
| 2014 |
Mohamedali KA, Cheung LH, Cao Y, Hittelman WN, Rosenblum MG. Abstract 4509: The fully human, proapoptotic fusion protein Granzyme B/VEGF121targets tumor vasculature and inhibits tumor growth Cancer Research. 74: 4509-4509. DOI: 10.1158/1538-7445.Am2014-4509 |
0.57 |
|
| 2013 |
Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG. The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth. Molecular Cancer Therapeutics. 12: 2055-66. PMID 23858102 DOI: 10.1158/1535-7163.Mct-13-0165 |
0.591 |
|
| 2013 |
Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG. Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Molecular Cancer Therapeutics. 12: 979-91. PMID 23493312 DOI: 10.1158/1535-7163.Mct-13-0002 |
0.627 |
|
| 2013 |
Chen N, Balasenthil S, Cao Y, Killary AM. Abstract C71: DEAR1 orchestrates selective control over the epithelial-mesenchymal transition axis of TGFβ's function Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C71 |
0.323 |
|
| 2013 |
Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG. Abstract 860: In vitro and in vivo studies of a novel, functionalized, completely human serine protease targeting Her2/neu. Activity against Herceptin- and multi-drug resistant tumor cells . Cancer Research. 73: 860-860. DOI: 10.1158/1538-7445.Am2013-860 |
0.616 |
|
| 2013 |
Mohamedali KA, Cheung LH, Cao Y, Hittelman WN, Rosenblum MG. Abstract 5479: The fully human pro-apoptotic fusion toxin Granzyme B/VEGF121targets vasculature and ablates tumor growth. Cancer Research. 73: 5479-5479. DOI: 10.1158/1538-7445.Am2013-5479 |
0.593 |
|
| 2013 |
Zhou H, Migliorini M, Cao Y, Cheung LH, Hittelman WN, Winkles JA, Rosenblum MG. Abstract 2185: Development and characterization of the fully human chimeric protein GrB-TWEAK targeting Fn14-positive solid tumor cells. Cancer Research. 73: 2185-2185. DOI: 10.1158/1538-7445.Am2013-2185 |
0.646 |
|
| 2012 |
Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG. Cell-targeting fusion constructs containing recombinant gelonin. Methods in Enzymology. 502: 167-214. PMID 22208986 DOI: 10.1016/B978-0-12-416039-2.00008-2 |
0.608 |
|
| 2012 |
Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Molecular Cancer Therapeutics. 11: 143-53. PMID 22090420 DOI: 10.1158/1535-7163.Mct-11-0519 |
0.637 |
|
| 2012 |
Mohamedali KA, Cheung LH, Cao Y, Rosenblum MG. Abstract 3874: A novel human fusion protein composed of the serine protease Granzyme B and VEGF121to target the vasculature of solid tumors Cancer Research. 72: 3874-3874. DOI: 10.1158/1538-7445.Am2012-3874 |
0.596 |
|
| 2012 |
Cao Y, Mohamedali KA, Chueng LH, Hittelman WN, Rosenblum MG. Abstract 3870: Construction and characterization of completely human serine protease therapeutics targeting Her2/neu Cancer Research. 72: 3870-3870. DOI: 10.1158/1538-7445.Am2012-3870 |
0.655 |
|
| 2012 |
Cao Y, Marks JW, Liu Z, Chueng LH, Hittelman WN, Rosenblum MG. Abstract 2730: Anti-Her2/neu immunotoxins: Impact of monovalent and bivalent designs onin vitroandin vivoantitumor efficacy Cancer Research. 72: 2730-2730. DOI: 10.1158/1538-7445.Am2012-2730 |
0.622 |
|
| 2011 |
Berstad ME, Berg K, Rosenblum M, Cao Y, Marks JD, Weyergang A. Abstract 3635: Improved efficacy of HER2 targeted-immunotoxins using photochemical internalization (PCI) Cancer Research. 71: 3635-3635. DOI: 10.1158/1538-7445.Am2011-3635 |
0.642 |
|
| 2011 |
Cao Y, Marks JW, Carroll S, Georgiou G, Hittelman WN, Rosenblum MG. Abstract 1759: Design optimization and characterization of novel herceptin-based immunotoxins for cancer therapy. Enhanced antitumor activity in vitro and in vivo Cancer Research. 71: 1759-1759. DOI: 10.1158/1538-7445.Am2011-1759 |
0.65 |
|
| 2010 |
Cao Y, Marks JD, Hittelman WN, Adams GP, Simmons HH, Cheung LH, Rosenblum MG. Abstract 2580: Single-chain antibody based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor effects Cancer Research. 70: 2580-2580. DOI: 10.1158/1538-7445.Am10-2580 |
0.57 |
|
| 2010 |
Liu Z, Zhang W, Ellis LM, Fan F, Cao Y, Cheung LH, Marks JW, Zhou H, Camphausen R, Rosenblum MG. Abstract 2576: Novel adnectin/rGelonin fusion constructs targeting the insulin-like growth factor(IGF1) receptor on tumor cells Cancer Research. 70: 2576-2576. DOI: 10.1158/1538-7445.Am10-2576 |
0.621 |
|
| 2009 |
Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Research. 69: 8987-95. PMID 19934334 DOI: 10.1158/0008-5472.Can-09-2693 |
0.612 |
|
| 2009 |
Gao Z, Zhang Q, Cao Y, Pan P, Bai F, Bai G. Preparation of novel magnetic cellulose microspheres via cellulose binding domain-streptavidin linkage and use for mRNA isolation from eukaryotic cells and tissues. Journal of Chromatography. A. 1216: 7670-6. PMID 19767004 DOI: 10.1016/J.Chroma.2009.09.028 |
0.475 |
|
| 2008 |
Zhang Q, Bai G, Chen JQ, Tian W, Cao Y, Pan PW, Wang C. Identification of antiviral mimetic peptides with interferon alpha-2b-like activity from a random peptide library using a novel functional biopanning method. Acta Pharmacologica Sinica. 29: 634-40. PMID 18430373 DOI: 10.1111/J.1745-7254.2008.00755.X |
0.389 |
|
| 2007 |
Chen J, Bai G, Cao Y, Gao Z, Zhang Q, Zhu Y, Yang W. One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique. Bioscience, Biotechnology, and Biochemistry. 71: 2655-62. PMID 17986790 DOI: 10.1271/Bbb.70190 |
0.447 |
|
| 2007 |
Cao Y, Tian W, Gao S, Yu Y, Yang W, Bai G. Immobilization staphylococcal protein a on magnetic cellulose microspheres for IgG affinity purification. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 35: 467-80. PMID 17922312 DOI: 10.1080/10731190601188331 |
0.461 |
|
| 2007 |
Zhang L, Liu CQ, Gao ZH, Cao Y, Bai G. [Research on the classification of streptomyces strain ZG0429 and purification of streptavidin]. Wei Sheng Wu Xue Bao = Acta Microbiologica Sinica. 47: 7-10. PMID 17436615 |
0.384 |
|
| 2007 |
Yu Y, Bai G, Liu C, Cao Y, Geng P, Yang W. One-step elimination of L-cysteine desulfhydrase from crude enzyme extracts of Pseudomonas sp. TS1138 using an immunomagnetic affinity matrix improves the enzymatic production of L-cysteine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 853: 247-53. PMID 17416559 DOI: 10.1016/J.Jchromb.2007.03.021 |
0.475 |
|
| 2007 |
Cao Y, Zhang Q, Wang C, Zhu Y, Bai G. Preparation of novel immunomagnetic cellulose microspheres via cellulose binding domain-protein A linkage and its use for the isolation of interferon alpha-2b. Journal of Chromatography. A. 1149: 228-35. PMID 17391680 DOI: 10.1016/J.Chroma.2007.03.032 |
0.469 |
|
| 2007 |
Chen J, Bai G, Yang Y, Geng P, Cao Y, Zhu Y. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay. Peptides. 28: 928-34. PMID 17267075 DOI: 10.1016/J.Peptides.2006.12.012 |
0.444 |
|
| 2006 |
Cao Y, Bai G, Zhang L, Bai F, Yang W. Immobilized iminobiotin on magnetic poly (vinyl alcohol) microspheres for single-step purification of streptavidin. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 34: 487-500. PMID 16893812 DOI: 10.1080/10731190600769370 |
0.394 |
|
| 2006 |
Cao Y, Bai G, Chen J, Tian W, Wang S, Yang W. Preparation and characterization of magnetic microspheres for the purification of interferon alpha-2b. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 833: 236-44. PMID 16490407 DOI: 10.1016/J.Jchromb.2006.02.001 |
0.416 |
|
| Show low-probability matches. |